État des négociations sur les médicaments de marque
L’APP fait partie du processus global canadien d’approbation et de remboursement des médicaments. Ce processus débute par une approbation réglementaire de Santé Canada après évaluation de l’efficacité, de la qualité et de l’innocuité des médicaments. Une fois approuvés par Santé Canada, tous les médicaments sont soumis à une évaluation des technologies de la santé (ETS) portant sur leur efficacité et leur rapport coût-efficacité. Au Canada, il y a deux organismes d’évaluation:
- l’Agence des médicaments du Canada (anciennement ACMTS)
- l’Institut national d’excellence en santé et en services sociaux (INESSS) au Québec.
Pour la majorité des nouveaux médicaments, le processus de négociation de l’APP débute après la publication d’une recommandation de l’Agence des médicaments du Canada ou de l’INESSS.
De concert avec nos partenaires, nous avons établi un processus d’accès temporaire (PAT) qui permettra aux patient.e.s d’avoir un accès précoce et provisoire à certains médicaments. Pour tout savoir sur le PAT, veuillez consultez notre page Web.
Les exportations à partir de notre base de données de négociations peuvent être téléchargées dans les formats .CSV et .JSON .
| Produit | Fabricant | État | Indication |
|---|---|---|---|
| Tevimbra (tislelizumab) | BeOne Medicines (Canada) ULC | Négociation envisagée | in combination with gemcitabine and platinum chemotherapy, for the first-line treatment of adult patients with recurrent or metastatic nasopharyngeal carcinoma (NPC). |
| Kisqali (ribociclib) | Novartis Pharmaceuticals Canada Inc. | Négociation envisagée | in combination with an aromatase inhibitor for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II-III early breast cancer at high risk of recurrence• In pre- or perimenopausal women, or men, the aromatase inhibitor should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist. |
| Kerendia (finerenone) | Bayer Inc. | Négociation envisagée | As an adjunct to standard of care in adults with heart failure with left ventricular ejection fraction (LVEF) ≥40% to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits. |
| Loqtorzi (toripalimab) | Apotex Inc. | Négociation envisagée | In combination with cisplatin and gemcitabine, for the first-line treatment of adults with metastatic or with recurrent, locally advanced nasopharyngeal carcinoma (NPC). |
| Loqtorzi (toripalimab) | Apotex Inc. | Négociation envisagée | for the treatment of adults with recurrent unresectable or metastatic nasopharyngeal carcinoma (NPC) with disease progression on or after a platinum-containing chemotherapy |
| Tzield (teplizumab) | Sanofi-Aventis Canada Inc. | Négociation envisagée | indicated to delay the onset of stage 3 type 1 diabetes (T1D) in adult and pediatric patients 8 years of age and older with stage 2 T1D |
| Tryngolza (Olezarsen ) | Theratechnologies Inc. | Négociation envisagée | As an adjunct to diet for the treatment of adults with familial chylomicronemia syndrome (FCS) to reduce triglyceride levels. |
| Imfinzi (durvalumab) | AstraZeneca Canada Inc. | Négociation envisagée | In combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy as neoadjuvant and adjuvant treatment, followed by adjuvant durvalumab monotherapy, for the treatment of adult patients with resectable gastric or gastroesophageal junction adenocarcinoma (GC/GEJC). |
| Amvuttra (vutrisiran) | Alnylam Netherlands B.V. | Négociation envisagée | Cardiomyopathy due to transthyretin-mediated amyloidosis |
| Elfabrio (pegunigalsidase alfa) | Chiesi Canada Corporation | Négociation envisagée | Maladie de Fabry |
| Isturisa (osilodrostat) | Recordati Rare Diseases Canada Inc. | Négociation envisagée | For the treatment of adult patients with Cushing’s disease who have persistent or recurrent hypercortisolism after primary pituitary surgery and/or irradiation, or for whom pituitary surgery is not an option. |
| Tecentriq (atezolizumab) | Hoffmann-La Roche Ltd. | Négociation envisagée | For the first-line treatment of patients with metastatic NSCLC whose tumours have high PD-L1 expression (PD-L1 stained greater than or equal to 50% of TCs or PD-L1 stained tumour-infiltrating immune cells [ICs] covering greater than or equal to 10% of the tumour area), as determined by a validated test and who do not have EGFR or ALK genomic tumour aberrations. |
| Vyvgart (efgartigimod alfa) | Argenx Canada Inc. | Négociation envisagée | Chronic inflammatory demyelinating polyneuropathy |
| Dupixent (dupilumab) | Sanofi Genzyme Canada | Négociation envisagée | Indicated as an add-on maintenance treatment in adult patients with chronic obstructive pulmonary disease (COPD) characterized by raised blood eosinophils inadequately controlled by the combination of an inhaled corticosteroid (ICS), a long-acting beta2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA), or on a combination of a LABA and a LAMA if ICS is not appropriate. |
| Dayvigo (lemborexant) | Eisai Limited | Négociation envisagée | Insomnie |
| Blenrep (belantamab mafodotin) (in combination with bortezomib and dexamethasone) | GlaxoSmithKline Inc. | Négociation envisagée | For the treatment of multiple myeloma in combination with bortezomib and dexamethasone (BVd) in adult patients who have received at least one prior therapy. |
| Blenrep (belantamab mafodotin) (in combination with pomalidomide and dexamethasone) | GlaxoSmithKline Inc. | Négociation envisagée | For the treatment of multiple myeloma in combination with pomalidomide and dexamethasone (Bpd) in adult patients who have received at least one prior therapy including lenalidomide. |
| Scemblix (asciminib) | Novartis Pharmaceuticals Canada Inc. | Négociation envisagée | For the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) who have previously received 1 tyrosine kinase inhibitor (second line). |
| Opzelura (ruxolitinib) | Incyte Biosciences Canada Corporation | Négociation envisagée | Nonsegmental vitiligo |